IMR Press / EJGO / Volume 42 / Issue 2 / DOI: 10.31083/j.ejgo.2021.02.2179
Open Access Original Research
Plasma concentration of piRNAs in breast cancer and its association with metastasis
Show Less
1 Department of Clinical Laboratory, The Third Affiliated Hospital of Guangzhou Medical University, 510150 Guangzhou, China
2 Department of Blood Transfusion, Dongguan Tung Wah Hospital, 523120 Dongguan, China
3 Center for Reproductive Medicine, The Third Affiliated Hospital of Guangzhou Medical University, 510150 Guangzhou, China
4 Key Laboratory for Reproductive Medicine of Guangdong; Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes; Key Laboratory for Major Obstetric Diseases of Guangdong Province, 510150 Guangzhou, China

These authors contributed equally.

Eur. J. Gynaecol. Oncol. 2021 , 42(2), 307–310; https://doi.org/10.31083/j.ejgo.2021.02.2179
Submitted: 27 June 2020 | Revised: 18 November 2020 | Accepted: 23 November 2020 | Published: 15 April 2021
Abstract

Objectives: Piwi-interacting RNAs (piRNAs), are a family of small, non-coding RNA transcipts, previously thought to silence gene expression in germ cells through the piRNA-PIWI complex. In recent studies, piRNAs were found to be prominently involved in the development and prognosis of malignant tumors. The study aims to identify differentially expressed circulating piRNAs in breast cancer patients. Methods: 8 piRNAs were tested using Real-time PCR assay in the plasma samples of 33 healthy subjects and 37 breast cancer patients. Results: In this study, we found that piR-651, piR-17458, and piR-20485 were significantly down-regulated in breast cancer patients when compared with healthy controls. Further, piR-20485 was found to be decreased in patients with metastatic disease relative to those with carcinoma in situ. Conclusion: These findings demonstrate that piRNAs are potential biomarkers in peripheral blood for breast cancer diagnosis.

Keywords
piRNA
Breast cancer
Plasma
Metastasis
Quick detection
Figures
Fig. 1.
Share
Back to top